

**Chemkart India Ltd**

18<sup>th</sup> May 2026

**To,**  
**BSE Limited**  
P. J. Towers,  
Dalal Street, Fort,  
Mumbai - 400001  
Security Code: 544442

**Subject: Investor Presentation – H2-FY26**

Dear Sir/Madam,

Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith the investor presentation, which is also uploaded on our website.

Kindly take the aforesaid information on record.

Thank you.

Yours sincerely,  
**For Chemkart India limited**

**Mr. Basavaraj Dalawai**  
**Designation – CFO**

**Place – Mumbai**





# Chemkart India Ltd

Investor Presentation - May 2026




This presentation and the accompanying slides (the “Presentation”), which have been prepared by Chemkart India Limited (the “Company”), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and shall not form the basis or be relied on in connection with any contract or binding commitment whatsoever. No offering of securities of the Company will be made except by means of a statutory offering document containing detailed information about the Company.

This Presentation has been prepared by the Company based on information and data which the Company considers reliable, but the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this Presentation. This Presentation may not be all inclusive and may not contain all the information that you may consider material. Any liability in respect of the contents of, or any omission from, this Presentation is expressly excluded.

Certain matters discussed in this Presentation may contain statements regarding the Company’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. These risks and uncertainties include, but are not limited to, the performance of the Indian economy and of the economies of various international markets, the performance of the industry in India and world-wide, competition, the company’s ability to successfully implement its strategy, the Company’s future levels of growth and expansion, technological implementation, changes and advancements, changes in revenue, income or cash flows, the Company’s market preferences and its exposure to market risks, as well as other risks. The Company’s actual results, levels of activity, performance or achievements could differ materially and adversely from results expressed in or implied by this Presentation. The Company assumes no obligation to update any forward-looking information contained in this Presentation. Any forward-looking statements and projections made by third parties included in this Presentation are not adopted by the Company and the Company is not responsible for such third-party statements and projections. All Maps used in the presentation are not to scale. All data, information, and maps are provided "as is" without warranty or any representation of accuracy, timeliness or completeness.




----- **Company Overview**



----- **Industry Overview**



----- **Strategic Overview**



----- **Half-Yearly Financial Performance**



----- **Historical Financial Performance**



----- **Investment Rationale**





## **Mission**

To drive growth and excellence in food and health ingredients through quality sourcing, trusted partnerships, and innovative, sustainable solutions that empower customer success.



## **Vision**

To be a global leader in end-to-end CDMO solutions and trusted distribution of food, health, and specialty ingredients, delivering quality, trust, innovation, and sustainable growth across the value chain.



**10+** Product Categories



**150+** Ingredients



**500+** Trusted Clients



**30K Sq.Ft** Warehouse



Certifications:  
**ISO 9001:2015 | FSSAI | ETC |**



**Pan-India**  
Distribution Network



(2 Year CAGR)  
Revenue: **26.9%**  
EBITDA: **17.6%**  
PAT: **19.6%**



(FY26)  
ROE: **15%**  
ROCE: **21%**





**Chemkart India Limited**, established in March 2015 and headquartered in Mumbai, is a B2B supplier of high-quality raw ingredients used in the manufacturing of nutritional, sports, and health supplements.

The company serves a broad spectrum of manufacturers across India, offering a diverse range of ingredients including amino acids like L-Leucine, L-Isoleucine, L-Valine, and L-Lysine HCL.

Since inception, the company has built strong relationships with both customers and suppliers and operates on a scalable distribution model, supported by effective inventory forecasting and supply chain responsiveness.

- **Incorporated in 2020** as a private company; became *Chemkart India Limited* in 2024.
- **B2B supplier** of raw ingredients for nutritional, sports, and health supplements.
- **Processes key amino acids & ingredients** like L-Leucine, L-Isoleucine, L-Valine, L-Lysine HCL, and more.
- **In-house blending & grinding facility** ensures product customization and quality control.
- **Strong customer & supplier relationships** built since inception.
- **Focus on operational efficiency**, inventory forecasting, and responsive supply chain management.
- **Serves manufacturers** of finished dietary and wellness supplements across India.
- The Company's business operations are further supported by its subsidiaries: **Easy Raw Materials Private Limited** and **Vinstar Biotech Private Limited**.








# Vision 2030: Global Biotechnology Leader

- Commissioning of EZRM SEZ Facility – India's first nutraceutical-focused SEZ hub
- Scale-up of novel technologies: liposomal, microencapsulation, nanoemulsion, beadlets
- Establish export-driven manufacturing foundation
- Establishment of R&D Innovation Center

- Full-service CDMO offerings: custom molecules → finished dosage forms



- Entry into integrated manufacturing of bioactive molecules
- Establishment of global offices – USA, Europe, Middle East

- Leadership as India's #1 CRDMO in Nutraceuticals & Personal Wellness
- Global footprint with 60% manufacturing driven revenues
- Fully integrated solutions: ingredients, formulations, regulatory, supply chain



**Chemkart India Limited (CIL)** announced the commencement of full-scale construction of a greenfield facility at its wholly owned subsidiary, **Easy Raw Materials Pvt. Ltd. (EZRM)**, located in the *JNPT Special Economic Zone (SEZ)*, Maharashtra.

This next-generation nutraceutical CDMO facility is designed for global-scale manufacturing, packaging, and export of health supplements with a strong focus on novel ingredient technologies such as microencapsulation, liposomal delivery systems, and enhanced bioavailability formats.

The nutraceutical formulations from our upcoming SEZ-based facility at JNPT, Maharashtra, are primarily aimed at export markets.

Following the Bhumi Pujan held on July 19, 2025, civil and infrastructure work is now in full swing. The SEZ-based facility is strategically positioned near India's largest container port, offering seamless access to global markets and duty-free benefits under SEZ policy.

### **Highlights of the EZRM SEZ Facility:**

- 4,120 sq.m plot leased for 60 years at JNPA SEZ, Raigad
- Integrated CDMO operations: Formulation, packaging, and global dispatch
- Dosage formats: Tablets, capsules, jars, sachets
- Built-in export readiness: SEZ-compliant labelling, documentation & logistics
- Novel technologies: Microencapsulation, liposomal ingredients, and enhanced bioavailability systems
- Modern infrastructure: QC labs, warehousing, utilities, admin block, and sustainability features



# Our upcoming facility JNPA



Projected Outlay for the Manufacturing Facility



## Project Progress Updates



**Civil foundation and plinth-level** development activities are progressing steadily in a phased manner across the manufacturing facility.



**Reinforcement and casting work for pile caps** in both utility and core manufacturing zones are actively under execution.



**Internal plinth beam filling, soil compaction, anti-termite treatment, and soling activities** are advancing in line with the planned project timeline.



**External brickwork and lift structure construction** have commenced, marking progress toward the next phase of infrastructure development.



**Utility infrastructure planning, process engineering documentation, and structural execution activities** continue as per the approved implementation schedule.



Civil foundation and plinth-level execution in progress



**As per the latest Daily Progress Report**, multiple civil and structural activities across plinth beam, compaction, anti-termite treatment, soling, and manufacturing area works are actively progressing under the project execution phase.



Foundation & Plinth Works



Reinforcement & Casting



Compaction, Anti-termite & Soling



Brickwork & Lift Structure Development



Utility Planning & Structural Execution



## Our Leading Product Portfolio

Glycine

Creatine Monohydrate 200 Mesh

Inositol

BCAA 2:1:1 (Leucine, Isoleucine, Valine)

L-Glutamine

L-Carnitine

N-Acetyl L-Cysteine (NAC)

Taurine

L-Glutathione (Reduced)


Whey Protein Concentrate 80%

## Clientele at a Glance





# Domestic Stronghold with Emerging Global Reach



■ Export ■ Domestic

● Warehousing facility in Bhiwandi, Maharashtra spans 28,259 sq. ft. across three floors, fully equipped for blending, grinding, packing, labelling, and sealing operations.



# Robust Storage & Processing Capabilities



**150+**  
Ingredients



**30000 Sq.ft**  
Warehouse



**50+**  
Employee  
Strength



**1.8MT/Day**  
Grinding  
Capacity



**1.5MT/Day**  
Blending  
Capacity



## Vinstar Biotech Limited

Supports science-led platforms in biotech, life sciences, chemicals, and R&D-driven innovation. Its involvement aligns with Chemkart's vision of building high-impact, sustainable manufacturing capacity in India.



## Easy Raw Materials Pvt. Ltd

Focused on the manufacturing & export of high-quality nutraceutical and wellness products, driven by sustainability, automation, R&D excellence & cutting-edge formulation technologies.



**Ankit Shailesh Mehta**  
**Chairman & Managing Director**

He holds a Bachelor's degree in (Chemical Engineering) & MBA in (Technology Management). With over 11 years of entrepreneurial experience including 4 years dedicated to the nutraceutical industry, he plays a pivotal role in steering Chemkart's strategic direction and long-term growth. He also oversees group companies such as Profoods Nutrition, Easy Raw Materials, and Vinstar Biotech.



**Parul Shailesh Mehta**  
**Promoter & Executive Director**

With 9 years of experience in the nutraceutical sector, she brings strong operational and strategic expertise. A science graduate with a Medical Laboratory Technology certification, she has led key functions including procurement, sales, logistics, compliance, and quality. She also plays leadership roles in group companies Profoods Nutrition, Easy Raw Materials, and Vinstar Biotech driving brand strategy, marketing, partnerships, and product line expansion.



**Shailesh Vinodrai Mehta**  
**Promoter & Executive Director**

A commerce graduate from the University of Bombay, he brings over 30 years of experience in the chemical sector through his proprietorship, Atul Chemicals, where he has led business expansion, quality control, and operational strategy. Appointed to the Board in July 2024 and regularized in September 2024, he also contributes his expertise to the nutraceutical and food supplement sector.



## ISO 9001:2015 Certified



## FSSAI License



## ISO 22000:2018 Certified




## HALAL Certified



## KOSHER Certified







----- **Company Overview**




----- **Industry Overview**



----- **Strategic Overview**



----- **Half-Yearly Financial Performance**



----- **Historical Financial Performance**



----- **Investment Rationale**





# Powering India's \$76 Billion Health Revolution



India's nutraceutical market is **growing at 10% CAGR**, projected to reach USD 76 billion by 2033, backed by rising health-conscious consumer spending.



A wellness-focused middle class and expanding elderly population are driving **sustained demand** for functional and personalized nutrition.




**Government incentives** like PLI schemes and FSSAI regulations are **boosting confidence** in domestic manufacturing and industry scalability.




India's Ayurvedic legacy and rising global demand for natural ingredients are positioning it as a **leading nutraceutical export hub**.


### Indian Nutraceuticals Market Size (USD Billions)



### Indian Nutraceuticals Product Share



### Global Nutraceuticals Market Size (USD Billions)



SOURCE: Grand View Research



# Trends Fueling the Next Wave of Nutraceutical Growth

01

**AYURVEDA 2.0**

India's 1,700+ medicinal plants are fueling demand for standardized herbs like turmeric, tulsi, and ashwagandha. Backed by modern extraction and global clinical validation, Ayurvedic blends are gaining popularity, with growing exports.

02

**CLEAN LABEL & PLANT BASED.**

Consumers prefer additive-free, transparent, and vegan products. This drives demand for natural ingredients in formats like herbal teas and gummies, prompting companies to meet global clean-label standards.

03

**PERSONALISED NUTRITION**


Tailored supplements based on genetics, lifestyle, and health data are rising. Microbiome, hormone, and age-specific solutions are growing, supported by wearables and health tech.

04


**R&D & BIOAVAILABILITY**

Focus is shifting to better absorption and delivery via nano emulsions and liposomal formats. Partnerships with research bodies are driving innovation in taste, stability, and efficacy.

SOURCES: Fortune Business Insights, IMARC Group, Grand View Research, Statista, ASSOCHAM-EY & IBEF




----- **Company Overview**




----- **Industry Overview**




----- **Strategic Overview**



----- **Half-Yearly Financial Performance**



----- **Historical Financial Performance**



----- **Investment Rationale**





## Strategic Advantages



### **Experienced Team:**

Strong leadership with deep industry knowledge.



### **Cost-Efficient Operations:**

Lean inventory system reduces cost and improves delivery.



### **Strong Relationships:**

Long-term ties with global suppliers and customers.



### **High-Margin Focus:**

Specializes in profitable specialty and performance chemicals.




### **Diverse Industry Reach:**

Serves pharma, agrochemicals, and personal care sectors.

## Path Ahead

### **Product Expansion:**

Our new manufacturing facility marks strategic entry into CDMO, expanding capabilities and offerings.



### **Vertical Integration:**

Enabling scalable growth and margin leadership through in-house, integrated manufacturing.



### **Enhanced R&D:**

Developing customized solutions for diverse client needs.



### **Policy Advantage:**

Benefiting from “Make in India” and PLI schemes to boost manufacturing and exports.



### **Global Reach:**

Expanding client base globally while strengthening existing partnerships.





*\*Some of the Pictures of Exhibitions & Interactions\**



## Strengthening Digital B2B Presence

By leveraging online B2B platforms, we've expanded nationwide visibility, generated high-quality leads, and strengthened our presence across chemical and nutraceutical industries.



## Customer-Centric Market Alignment

Our sales team actively engages with clients to gather insights and feedback on emerging industry trends, enabling us to tailor our product procurement to meet evolving market demands.



## Expanding Reach Through Social Media

We actively leverage platforms like Facebook, Instagram, and YouTube to connect with a broader audience, enhance customer engagement, and strengthen brand presence across digital touchpoints.



## Boosting Brand Presence through Exhibitions

We actively participate in industry exhibitions and fairs, leveraging these platforms to showcase our products and enhance brand visibility.



----- **Company Overview**



----- **Industry Overview**



----- **Strategic Overview**



----- **Half-Yearly Financial Performance**



----- **Historical Financial Performance**



----- **Investment Rationale**





**Ankit Shailesh Mehta**  
**Chairman & Managing Director**

In FY26, the Company delivered a measured performance amid a challenging global operating environment, impacted by supply chain disruptions, pricing corrections across key product categories, and uncertainties surrounding US tariff policies, which affected demand from certain export-oriented clients. Despite these headwinds, the Company reported a consolidated revenue of INR 21,482.91 lakhs, supported by healthy volume growth of approximately 7.1%, reflecting steady underlying demand.

The Company continued to strengthen its long-term growth foundation, with steady progress in the development of the EZRM SEZ manufacturing facility. This marks a key milestone in enhancing manufacturing capabilities and improving export competitiveness, positioning the Company for the next phase of growth.

The Company will focus more on research and development, product innovation, and advanced nutraceutical technologies going forward, with the objective of strengthening its value-added offerings and driving long-term sustainable growth.






As on 31st March 2026, the Company maintained strong business visibility with advance and open orders exceeding INR 6,526 lakhs, along with a robust sales and project pipeline. This provides confidence in a strong growth trajectory in the coming periods.

Looking ahead, the Company remains well-positioned to benefit from the rapidly expanding nutraceutical industry, which is expected to grow at a double-digit CAGR in India. Backed by strategic investments, an agile business model, and favourable industry dynamics, the Company is poised to scale its revenue and strengthen its market presence.

We sincerely thank our investors, customers, business partners, and employees for their continued trust and support as we continue building a scalable and future-ready nutraceutical platform.



# Key Financial Highlights





# Consolidated Income Statement

Particulars (Rs. Lacs)	H2 FY26	H2 FY25	Y-o-Y	H1 FY26	H-o-H	FY26	FY25	Y-o-Y
<b>Revenue from Operations</b>	<b>11,160.4</b>	<b>9,015.2</b>	<b>23.8%</b>	<b>10,322.6</b>	<b>8.1%</b>	<b>21,482.9</b>	<b>20,327.9</b>	<b>5.7%</b>
Cost of Materials Consumed	141.1	434.8		1,005.2		1,146.3	748.6	
Purchase of Stock in Trade	10,364.9	7,490.7		7,494.4		17,859.3	17,123.4	
Changes in Inventories in Stock in Trade	-1,191.7	-379.4		-31.6		-1,223.3	-1,469.5	
Employee Expenses	170.1	105.3		190.2		360.4	217.9	
Other Expenses	273.8	99.7		248.7		522.5	420.5	
<b>EBITDA</b>	<b>1,402.1</b>	<b>1,264.2</b>	<b>10.9%</b>	<b>1,415.6</b>	<b>-1.0%</b>	<b>2,817.7</b>	<b>3,287.1</b>	<b>-14.3%</b>
<b>EBITDA Margin (%)</b>	<b>12.6%</b>	<b>14.0%</b>		<b>13.7%</b>		<b>13.1%</b>	<b>16.2%</b>	
Other Income	-2.3	68.9		68.8		66.5	217.8	
Depreciation	24.3	48.4		25.3		49.7	70.3	
<b>EBIT</b>	<b>1,375.5</b>	<b>1,284.8</b>	<b>7.1%</b>	<b>1,459.0</b>	<b>-5.7%</b>	<b>2,834.5</b>	<b>3,434.6</b>	<b>-17.5%</b>
<b>EBIT Margin (%)</b>	<b>12.3%</b>	<b>14.3%</b>		<b>14.1%</b>		<b>13.2%</b>	<b>16.9%</b>	
Finance Cost	67.4	96.5		78.2		145.7	187.1	
<b>Profit before Tax</b>	<b>1,308.1</b>	<b>1,188.3</b>	<b>10.1%</b>	<b>1,380.8</b>	<b>-5.3%</b>	<b>2,688.9</b>	<b>3,247.5</b>	<b>-17.2%</b>
Tax	357.5	298.6		365.9		723.4	795.6	
Minority interest in Profit/(Loss)	0.3	0.1		-0.5		-	-1.4	
<b>Profit After Tax</b>	<b>950.3</b>	<b>889.6</b>	<b>6.8%</b>	<b>1,015.4</b>	<b>-6.4%</b>	<b>1,965.5</b>	<b>2,453.3</b>	<b>-19.9%</b>
<b>PAT Margin (%)</b>	<b>8.5%</b>	<b>9.9%</b>		<b>9.8%</b>		<b>9.1%</b>	<b>12.1%</b>	
EPS (As per Profit after Tax)	7.9	16.3		9.5		17.3	26.1	



# Standalone Income Statement

Particulars (Rs. Lacs)	H2 FY26	H2 FY25	Y-o-Y	H1 FY26	H-o-H	FY26	FY25	Y-o-Y
<b>Revenue from Operations</b>	<b>11,050.8</b>	<b>9,015.2</b>	<b>22.6%</b>	<b>10,208.7</b>	<b>8.2%</b>	<b>21,259.5</b>	<b>20,327.9</b>	<b>4.6%</b>
Cost of Materials Consumed	141.1	434.8		1,005.2		1,146.3	748.6	
Purchase of Stock in Trade	10,270.6	7,490.7		7,382.6		17,653.2	17,123.4	
Changes in Inventories in Stock in Trade	-1,198.8	-379.4		-18.8		-1,217.5	-1,469.5	
Employee Expenses	146.6	102.1		165.4		312.0	214.7	
Other Expenses	245.0	91.6		226.9		471.9	410.6	
<b>EBITDA</b>	<b>1,446.3</b>	<b>1,275.5</b>	<b>13.4%</b>	<b>1,447.3</b>	<b>-0.1%</b>	<b>2,893.6</b>	<b>3,300.1</b>	<b>-12.3%</b>
<b>EBITDA Margin (%)</b>	<b>13.1%</b>	<b>14.1%</b>		<b>14.2%</b>		<b>13.6%</b>	<b>16.2%</b>	
Other Income	10.1	70.0		86.2		96.3	218.9	
Depreciation	21.5	39.3		22.4		43.9	61.2	
<b>EBIT</b>	<b>1,434.9</b>	<b>1,306.2</b>	<b>9.9%</b>	<b>1,511.0</b>	<b>-5.0%</b>	<b>2,945.9</b>	<b>3,457.9</b>	<b>-14.8%</b>
<b>EBIT Margin (%)</b>	<b>13.0%</b>	<b>14.5%</b>		<b>14.8%</b>		<b>13.9%</b>	<b>17.0%</b>	
Finance Cost	67.2	96.3		78.1		145.3	186.7	
<b>Profit before Tax</b>	<b>1,367.7</b>	<b>1,210.0</b>	<b>13.0%</b>	<b>1,432.9</b>	<b>-4.6%</b>	<b>2,800.6</b>	<b>3,271.1</b>	<b>-14.4%</b>
Tax	357.5	298.6		365.9		723.4	795.6	
<b>Profit After Tax</b>	<b>1,010.2</b>	<b>911.4</b>	<b>10.8%</b>	<b>1,067.0</b>	<b>-5.3%</b>	<b>2,077.2</b>	<b>2,475.5</b>	<b>-16.1%</b>
<b>PAT Margin (%)</b>	<b>9.1%</b>	<b>10.1%</b>		<b>10.5%</b>		<b>9.8%</b>	<b>12.2%</b>	
EPS (As per Profit after Tax)	8.4	16.3		10.0		18.2	26.1	



# Consolidated Balance Sheet

Assets (Rs. Lacs)	Mar-26	Mar-25
<b>Non - Current Assets</b>		
a)Property, plant and equipment and Intangible Assets		
i)Property, plant and equipment	833.8	867.5
ii) Intangible Assets	1.2	1.2
iii) Capital Work in Progress	486.8	16.0
b)Non-current investments		
c)Deferred Tax Assets (net)	-	-
d)Other Non-current Assets	1,517.1	24.6
<b>Total Non - Current Assets</b>	<b>2,838.9</b>	<b>909.2</b>
<b>Current Assets</b>		
a) Inventories	3,472.6	2,249.4
b) Trade receivables	4,997.6	4,610.9
c) Cash and cash equivalents	3,864.5	283.1
d) Short term loans and advances	404.6	531.5
e) Other current assets	92.8	59.8
<b>Total Current Assets</b>	<b>12,832.2</b>	<b>7,734.7</b>
<b>Total Assets</b>	<b>15,671.1</b>	<b>8,643.9</b>

Equity And Liabilities (Rs. Lacs)	Mar-26	Mar-25
<b>Shareholders Funds</b>		
(a) Equity share capital	1,209.9	949.9
(b)Reserves and Surplus	11,763.1	4,378.7
(c) Minority Interest	-	-0.4
<b>Total Equity</b>	<b>12,973.0</b>	<b>5,328.2</b>
<b>Non - Current Liabilities</b>		
a) Long Term Borrowings	-	10.2
b) Deferred tax liabilities (net)	11.2	9.0
c) Long term provision	8.0	5.9
<b>Total Non - Current Liabilities</b>	<b>19.2</b>	<b>25.1</b>
<b>Current Liabilities</b>		
a) Short Term Borrowings	495.3	1,692.6
b) Trade payables		
(i)Total Outstanding dues of Micro & Small Enterprises	65.3	79.9
(ii) Total Outstanding dues Creditors other than Micro & Small Enterprises	1,725.6	1,071.3
c)Other current liabilities	28.4	60.7
d)Short Term Provisions	364.4	386.1
<b>Total Current Liabilities</b>	<b>2,678.9</b>	<b>3,290.6</b>
<b>Total Equity and Liabilities</b>	<b>15,671.1</b>	<b>8,643.9</b>



# Standalone Balance Sheet

Assets (Rs. Lacs)	Mar-26	Mar-25
<b>Non - Current Assets</b>		
a)Property, plant and equipment and Intangible Assets		
i)Property, plant and equipment	491.7	519.5
ii) Intangible Assets	0.0	0.0
b)Non-current investments	650.5	2.0
c)Deferred Tax Assets (net)	0.0	0.0
d)Other Non-current Assets	1,513.3	5.0
<b>Total Non - Current Assets</b>	<b>2,655.4</b>	<b>526.5</b>
<b>Current Assets</b>		
a) Inventories	3,466.9	2,249.4
b) Trade receivables	4,997.5	4,610.9
c) Cash and cash equivalents	3,649.5	278.3
d) Short term loans and advances	921.8	936.5
e) Other current assets	74.5	61.0
<b>Total Current Assets</b>	<b>13,110.2</b>	<b>8,136.0</b>
<b>Total Assets</b>	<b>15,765.6</b>	<b>8,662.5</b>


Equity And Liabilities (Rs. Lacs)	Mar-26	Mar-25
<b>Shareholders Funds</b>		
(a) Equity share capital	1,209.9	949.9
(b)Reserves and Surplus	11,895.9	4,400.9
(c) Minority Interest	0.0	0.0
<b>Total Equity</b>	<b>13,105.8</b>	<b>5,350.8</b>
<b>Non - Current Liabilities</b>		
a) Long Term Borrowings	0.0	10.2
b) Deferred tax liabilities (net)	11.2	9.0
c) Long term provision	7.3	5.9
<b>Total Non - Current Liabilities</b>	<b>18.4</b>	<b>25.1</b>
<b>Current Liabilities</b>		
a) Short Term Borrowings	495.3	1,692.6
b) Trade payables		
(i)Total Outstanding dues of Micro & Small Enterprises	65.3	79.9
(ii) Total Outstanding dues Creditors other than Micro & Small Enterprises	1,720.2	1,070.4
c)Other current liabilities	25.7	60.5
d)Short Term Provisions	334.9	383.2
<b>Total Current Liabilities</b>	<b>2,641.4</b>	<b>3,286.6</b>
<b>Total Equity and Liabilities</b>	<b>15,765.6</b>	<b>8,662.5</b>

Particulars (Rs. Lacs)	Mar-26	Mar-25
<b>Cash Flow from Operating Activities</b>		
Profit before Tax	<b>2,688.9</b>	<b>3,247.5</b>
Adjustment for Non-Operating Items	224.9	224.9
<b>Operating Profit before Working Capital Changes</b>	<b>2,913.8</b>	<b>3,472.5</b>
Changes in Working Capital	-2,418.1	-2,491.8
<b>Cash Generated/Used from Operations</b>	<b>495.7</b>	<b>980.6</b>
Less: Direct Taxes paid	-768.2	-610.7
<b>Net Cash from Operating Activities</b>	<b>-272.5</b>	<b>369.9</b>
<b>Cash Flow from Investing Activities</b>	<b>-486.8</b>	<b>-423.8</b>
<b>Cash Flow from Financing Activities</b>	<b>4,340.8</b>	<b>330.4</b>
<b>Net Increase/(Decrease) in Cash and Cash equivalents</b>	<b>3,581.4</b>	<b>276.5</b>




# Standalone Cashflow Statement


Particulars (Rs. Lacs)	Mar-26	Mar-25
<b>Cash Flow from Operating Activities</b>		
Profit before Tax	<b>2,800.6</b>	<b>3,271.1</b>
Adjustment for Non-Operating Items	178.5	215.9
<b>Operating Profit before Working Capital Changes</b>	<b>2,979.1</b>	<b>3,487.0</b>
Changes in Working Capital	-2,602.8	-2,901.8
<b>Cash Generated/Used from Operations</b>	<b>376.2</b>	<b>585.2</b>
Less: Direct Taxes paid	-721.2	-610.7
<b>Net Cash from Operating Activities</b>	<b>-345.0</b>	<b>-25.6</b>
<b>Cash Flow from Investing Activities</b>	<b>-16.0</b>	<b>-33.3</b>
<b>Cash Flow from Financing Activities</b>	<b>3,732.2</b>	<b>330.4</b>
<b>Net Increase/(Decrease) in Cash and Cash equivalents</b>	<b>3,371.2</b>	<b>271.6</b>




----- **Company Overview**



----- **Industry Overview**



----- **Strategic Overview**



----- **Half-Yearly Financial Performance**



----- **Historical Financial Performance**






----- **Investment Rationale**










# Segment-Wise Revenue Contribution




Product Category	FY24	FY25	FY26
Amino Acids	6,176.68	9,025.45	10,320.2
Health Supplement	1,642.95	2,410.53	2,414.1
Herbal Extract	416.83	331.78	418.1
Nucleotide	194.43	179.31	187.7
Protein	361.21	618.82	490.3
Sports Nutrition	3,289.13	6,755.84	6,562.7
Vitamin	899.91	465.28	488.0
Other	221.55	540.84	378.5
<b>Total</b>	<b>13,202.69</b>	<b>20,327.85</b>	<b>21,259.5</b>




# Key Financial Highlights




\*Consolidated Numbers\*




----- **Company Overview**



----- **Industry Overview**



----- **Strategic Overview**



----- **Half-Yearly Financial Performance**



----- **Historical Financial Performance**



----- **Investment Rationale**





## Profitable Product Mix

Specialty chemicals and nutraceuticals across pharma, personal care, and B2B segments, offering strong profit potential.



## Strong Customer Network

Focused on B2B, building trusted relationships to expand customers and drive sustainable nutraceutical growth.



## Greenfield Expansion

Investing in EZRM's greenfield manufacturing project to improve margins, reduce dependency, and support CDMO operations.



## China Plus One Strategy

Expanding manufacturing into microencapsulation, liposomal, and bioavailability systems to diversify supply and drive innovation.



## Policy Support

Capitalizing on "Make in India" and Production Linked Incentive (PLI) schemes to accelerate domestic manufacturing and expand exports.



## Expanding Globally

Expanding presence in existing markets and entering new geographies to boost growth and diversify risks.

Company



**Chemkart India Limited**

CIN: L51220MH2020PLC338631

Email ID: [investors@chemkart.com](mailto:investors@chemkart.com)

Tel: + 91 9136383828

Website: [www.chemkart.com](http://www.chemkart.com)

---

**Thank You!**

---

Investor Relations Partner



**X-B4 Advisory LLP**

Rasika Sawant / Aagam Shah

Tel: +91 95944 57518 / +91 8850166932

Email ID: [rasika@x-b4.com](mailto:rasika@x-b4.com) / [aagam@x-b4.com](mailto:aagam@x-b4.com)

Website: [www.x-b4.com](http://www.x-b4.com)

